To download our documents

Live stock price

OSE Immunotherapeutics is listed since 30th March 2015 on the regulated market of Euronext Paris

Share price





Type of listing


Number of outstanding shares

21,651,101 shares as of September 27, 2023


Eligible to Long-Only Deferred Settlement Service

Financial calendar

This calendar is indicative and may be amended. Financial results are published after market close (Euronext Growth Paris).

27 March 2024

Annual financial results 2023

19 June 2024

General shareholders' meeting

26 September 2024

Half-year results 2024


Read more
Invest Securities
Jamila El Bougrini
Kepler Cheuvreux
Pierre-Alexandre Desir
Soo Romanoff

Analyst reports

Read more
18/04/2024 Invest Securities : Upfront de 48M$ confirmé, Phase III Tedopi sécurisée
12/04/2024 Edison: Funding accelerates Tedopi clinical development
19/03/2024 Edison: One step closer to key data readouts

Regulated information

Read more
27/09/2023 Exercise of 2023 share subscription warrants at September 27, 2023
12/07/2023 Exercise of 2023 share subscription warrants at July 12, 2023

General shareholders' meetings

Read more

General Shareholders' Meeting 2023

All the documents below are in French (except the and "Voting form"

Financial information and publications

Read more
2023 First-half 2023 financial report (in French)
2023 Auditors's report on first-half 2023 financial report (in French)
2023 2022 Universal registration document

To receive OSE Immunotherapeutics’ latest news